D. Selley

发表

Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment

E. Nestler, D. Selley, C. Breivogel, 1997, Brain Research.

Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,u and Correlation of in Vitro, Preclinical, and Clinical Data

D. Selley, G. M. Pollack, J. C. Kalvass, 2007, Journal of Pharmacology and Experimental Therapeutics.

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

Benjamin F. Cravatt, Steven G. Kinsey, L. Parsons, 2008, Nature chemical biology.

Cannabinoid CB1 receptor‐interacting proteins: novel targets for central nervous system drug discovery?

D. Selley, Tricia H. Smith, L. Sim-Selley, 2010, British journal of pharmacology.

Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G‐protein activation

D. Selley, C. Breivogel, A. Zimmer, 2001, Journal of neurochemistry.

Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPγS Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity*

D. Selley, C. Breivogel, S. Childers, 1998, The Journal of Biological Chemistry.

Effects of sodium on agonist efficacy for G‐protein activation in μ‐opioid receptor‐transfected CHO cells and rat thalamus

D. Selley, S. Childers, Q. Liu, 2000, British journal of pharmacology.

Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.

Kendra M. Haney, D. Selley, Derong Ding, 2012, Organic & biomolecular chemistry.

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

D. Selley, I. Beletskaya, Yunyun Yuan, 2013, Bioorganic & medicinal chemistry letters.

Essential role for RGS9 in opiate action

E. Nestler, R. Neve, D. Selley, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

D. Selley, I. Beletskaya, Yunyun Yuan, 2013, Bioorganic & medicinal chemistry letters.

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

D. Selley, I. Beletskaya, Yunyun Yuan, 2011, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

D. Selley, R. Westkaemper, W. Dewey, 2009, Journal of medicinal chemistry.

Differences in G-protein activation by μ-and δ-opioid, and cannabinoid, receptors in rat striatum

D. Selley, S. Childers, R. Xiao, 1996 .

1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.

D. Selley, B. Martin, J. Wiley, 2005, Bioorganic & medicinal chemistry letters.

Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

G. Hynd, D. Selley, Ming-Jung Wu, 2005, Bioorganic & medicinal chemistry.

In vitro and in vivo functional profile characterization of 17‐cyclopropylmethyl‐3,14&bgr;‐dihydroxy‐4,5&agr;‐epoxy‐6&agr;‐(isoquinoline‐3‐carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator

D. Selley, Yunyun Yuan, Yan Zhang, 2018, European journal of pharmacology.

Differential Tolerance to FTY720-Induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of Sphingosine-1-Phosphate Receptor Adaptation

D. Selley, A. Lichtman, J. Burston, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1–Mediated Antinociceptive and Gastroprotective Effects

D. Selley, B. Cravatt, L. Wise, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approaches.

Mostafa H. Ahmed, G. Kellogg, D. Selley, 2014, Bioorganic & medicinal chemistry letters.

Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum.

D. Selley, S. Childers, R. Xiao, 1996, European journal of pharmacology.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays

D. Selley, A. Lichtman, B. Thomas, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells

D. Selley, A. Lichtman, D. Gewirtz, 2013 .

Prolonged reversal of morphine tolerance with no reversal of dependence by protein kinase C inhibitors

D. Selley, S. Welch, W. Dewey, 2002, Brain Research.

Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor.

D. Selley, Hongguang Ma, Yan Zhang, 2021, Bioorganic & medicinal chemistry letters.

Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors

D. Selley, C. Thompson, K. Rice, 2004, Journal of Pharmacology and Experimental Therapeutics.

Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol

D. Selley, M. LeDoux, M. Khan, 2019, Experimental Neurology.

Endomorphin‐Stimulated [35S]GTPγS Binding in Rat Brain: Evidence for Partial Agonist Activity at μ‐Opioid Receptors

D. Selley, S. Childers, L. J. Sim, 1998 .

Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice

L. Hrubá, D. Selley, B. Cravatt, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers.

D. Selley, S. Stevens Negus, Hongguang Ma, 2022, Bioorganic chemistry.

Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry.

Bethany A. Reinecke, D. Selley, J. An, 2020, ACS medicinal chemistry letters.

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

D. Selley, W. Dewey, Saheem A. Zaidi, 2013, Journal of medicinal chemistry.

D2 inhibition of stimulated Fos immunoreactivity in cultured tyrosine hydroxylase-ir hypothalamic neurons

D. Selley, M. Morris, L. J. Sim, 1994, Brain Research.

The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects

D. Selley, A. Lichtman, S. Kinsey, 2011, Neuropharmacology.

Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Δ9‐tetrahydrocannabinol exposure

D. Selley, J. Burston, J. Wiley, 2010, British journal of pharmacology.

Guanine nucleotide regulation of [125Iβ-endorphin binding to NG108-15 and SK-N-SH cell membranes: specific cation requirements

D. Selley, J. Bidlack, 1989, Brain Research.

Guanine Nucleotide Regulation of [125I]β‐Endorphin Binding to Rat Brain Membranes: Monovalent Cation Requirement

D. Selley, J. Bidlack, C. Tyler, 1988, Journal of neurochemistry.

Opioid inhibition of adenylyl cyclase in membranes from pertussis toxin-treated NG108-15 cells.

D. Selley, C. Breivogel, S. Childers, 1998, Journal of receptor and signal transduction research.

A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists

D. Selley, K. Rice, T. Prisinzano, 2022, Molecules.

ArticleA Journey Through Diastereomeric Space: The Design

D. Selley, K. Rice, T. Prisinzano, 2022 .

Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment.

Boshi Huang, D. Selley, W. Dewey, 2022, Journal of medicinal chemistry.

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

D. Selley, J. Streicher, W. Dewey, 2016, ACS chemical neuroscience.

Mutation of Putative GRK Phosphorylation Sites in the Cannabinoid Receptor 1 (CB1R) Confers Resistance to Cannabinoid Tolerance and Hypersensitivity to Cannabinoids in Mice

K. Mackie, H. Bradshaw, D. Selley, 2014, The Journal of Neuroscience.

3-Substituted Pyrazole Analogs of the Cannabinoid Type 1 (CB1) Receptor Antagonist Rimonabant: Cannabinoid Agonist-Like Effects in Mice via Non-CB1, Non-CB2 Mechanism

D. Selley, J. Wiley, Srinivas Gadthula, 2012, Journal of Pharmacology and Experimental Therapeutics.

3-Substituted Pyrazole Analogs of the CB 1 Antagonist Rimonabant: Cannabinoid Agonist-Like Effects in Mice Via Non-CB 1 , Non-CB 2 Mechanism

D. Selley, J. Wiley, Srinivas Gadthula, 2011 .

Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions.

D. Selley, S. Childers, C. E. Maher, 2000, Biochemical pharmacology.

1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.

D. Selley, B. Martin, J. Wiley, 2010, Bioorganic & medicinal chemistry.

Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system?

D. Selley, S. Welch, L. Sim-Selley, 2013, Life sciences.

Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.

D. Selley, Paul A. Smith, S. Welch, 2007, European journal of pharmacology.

Sphingosine and Its Analog, the Immunosuppressant 2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact with the CB1 Cannabinoid Receptor

S. Milstien, S. Spiegel, D. Selley, 2006, Molecular Pharmacology.

Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497

D. Selley, L. Wise, A. Lichtman, 2016, Journal of basic and clinical physiology and pharmacology.

FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration

D. Selley, B. Cravatt, A. Thorpe, 2010, Neuropsychopharmacology.

D. Selley, B. Martin, J. Wiley, 2008, Journal of Pharmacology and Experimental Therapeutics.

Signaling pathways involved in the development of cannabinoid tolerance.

D. Selley, B. Martin, L. Sim-Selley, 2004, Trends in pharmacological sciences.

Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids

D. Selley, M. Banks, S. Negus, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

D. Selley, W. Dewey, Yunyun Yuan, 2011, ACS chemical neuroscience.

Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

D. Selley, I. Beletskaya, W. Dewey, 2012, Journal of medicinal chemistry.

A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.

D. Selley, Seth M. Dever, N. El-Hage, 2013, MedChemComm.

Acute and Chronic Effects of Opioids on δ and μ Receptor Activation of G Proteins in NG108‐15 and SK‐N‐SH Cell Membranes

D. Selley, C. Breivogel, S. Childers, 1997 .

mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine.

D. Selley, S. Childers, T. Sexton, 2001, Biochemical pharmacology.

Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats

Amy R. Johnson, D. Selley, M. Banks, 2018, Neuropsychopharmacology.

Full FAAH inhibition combined with partial monoacylglycerol lipase inhibition: Augmented and sustained antinociceptive effects with reduced cannabimimetic side effects in mice

L. Hrubá, D. Selley, L. Wise, 2015 .

Prolonged Monoacylglycerol Lipase Blockade Causes Equivalent Cannabinoid Receptor Type 1 Receptor–Mediated Adaptations in Fatty Acid Amide Hydrolase Wild-Type and Knockout Mice

D. Selley, J. Long, B. Cravatt, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Early adolescent nicotine exposure affects later-life cocaine reward in mice

D. Selley, L. Wise, F. Carroll, 2016, Neuropharmacology.

Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D2 and D3 Receptors

D. Grandy, D. Selley, M. Reith, 2016, Neurochemical Research.

Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.

D. Selley, M. Banks, S. Negus, 2022, ACS chemical neuroscience.

Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.

Boshi Huang, D. Selley, W. Dewey, 2022, Journal of medicinal chemistry.

Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites

C. Bass, W. Lowther, D. Selley, 2017, Molecular Pharmacology.

Cannabinoid Receptor Interacting Protein ( CRIP ) 1 a competition with β-arrestin for CB 1 receptor binding sites

C. Bass, W. Lowther, D. Selley, 2016 .

Cannabinoid Receptor–Interacting Protein 1a Modulates CB1 Receptor Signaling and Regulation

Jordan O. Cox, K. Mackie, M. Elphick, 2015, Molecular Pharmacology.

Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems

C. Bass, D. Selley, S. Childers, 2013, Journal of neurochemistry.

CB1 Cannabinoid Receptor Activity Is Modulated by the Cannabinoid Receptor Interacting Protein CRIP 1a

M. Elphick, D. Selley, K. Wallis, 2007, Molecular Pharmacology.

CB 1 Cannabinoid Receptor Activity Is Modulated by the Cannabinoid Receptor Interacting Protein CRIP 1 a

M. Elphick, D. Selley, K. Wallis, 2007 .

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators.

D. Selley, W. Dewey, Hongguang Ma, 2019, Journal of medicinal chemistry.

Effect of strain and sex on μ opioid receptor-mediated G-protein activation in rat brain

D. Selley, M. Picker, D. Morgan, 2003, Brain Research Bulletin.

Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain

P. T. Nguyen, D. E. Selley, L. J. Sim-Selley, 2010, NeuroImage.

Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain

D. Selley, A. Lichtman, P. Knapp, 2016, Neurobiology of Disease.

Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins.

D. Selley, C. Breivogel, S. Childers, 1993, Molecular pharmacology.

Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.

Boshi Huang, D. Selley, Chongguang Chen, 2021, Bioorganic chemistry.

RGS9 Modulates Dopamine Signaling in the Basal Ganglia

Johannes Schwarz, David Self, Robert R Luedtke, 2003, Neuron.

Autoradiographic visualization in brain of receptor-G protein coupling using [35S]GTP gamma S binding.

D. Selley, S. Childers, L. J. Sim, 1997, Methods in molecular biology.

Autoradiographic Visualization in Brain of Receptor-G Protein Coupling Using [ 35 S]GTPγS Binding

D. Selley, S. Childers, L. J. Sim, 1997 .

In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding.

D. Selley, S. Childers, D E Selley, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.

Boshi Huang, D. Selley, P. Knapp, 2021, Journal of medicinal chemistry.

Personality: Neurobehavioural Foundation and Pharmacological Protocols

Stephanie A. Carmack, C. McDougle, D. Posey, 2014 .

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

D. Selley, Chongguang Chen, L. Liu-Chen, 2019, ACS chemical neuroscience.

Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion.

D. Selley, W. Dewey, H. Akbarali, 2018, ACS chemical neuroscience.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

G. Kellogg, D. Selley, P. Mosier, 2015, Bioorganic & medicinal chemistry.

Long-Term Administration of Δ9-Tetrahydrocannabinol Desensitizes CB1-, Adenosine A1-, and GABAB-Mediated Inhibition of Adenylyl Cyclase in Mouse Cerebellum

D. Selley, B. Martin, M. Cassidy, 2004, Molecular Pharmacology.

Inhibition of Adenylyl Cyclase in Mouse Cerebellum

D. Selley, B. Martin, M. Cassidy, 2004 .

μ-Opioid agonist-stimulated [ 35 S ]GTPγS binding in guinea pig hypothalamus: effects of estrogen

D. Selley, M. Kelly, Yuan Fang, 1998, Brain Research.

6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.

D. Selley, W. Dewey, Saheem A. Zaidi, 2016, ACS chemical neuroscience.

Sphingosine‐1‐phosphate receptors mediate neuromodulatory functions in the CNS

S. Milstien, S. Spiegel, D. Selley, 2009, Journal of neurochemistry.

Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation.

D. Selley, Hu Yang, W. Dewey, 2017, ACS Medicinal Chemistry Letters.

Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system

Peter T. Nguyen, D. Selley, D. Nomura, 2010, Nature Neuroscience.

Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration

D. Selley, B. Martin, George D. Dalton, 2006, Molecular Pharmacology.

In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5 '-[ y-[ 35 S ] thiol-triphosphate binding ( opioid receptor / cannabinoid receptor / ' y-aminobutyric acid type B receptor )

D. Selley, S. Childers, L. J. Sim, 2005 .

Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats.

D. Selley, S. Welch, L. Sim-Selley, 2004, European journal of pharmacology.

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

D. Selley, A. Nicola, P. Knapp, 2016, Bioorganic & medicinal chemistry.

Chronic Heroin Self-Administration Desensitizes μ Opioid Receptor-Activated G-Proteins in Specific Regions of Rat Brain

L. Vogt, D. Selley, S. Childers, 2000, The Journal of Neuroscience.

Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.

D. Selley, B. Cravatt, A. Lichtman, 2015, Cell reports.

Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells

D. Selley, A. Lichtman, D. Gewirtz, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

D. Selley, W. Dewey, H. Akbarali, 2019, Journal of medicinal chemistry.

Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.

D. Selley, S. Welch, L. Sim-Selley, 2012, Biochemical pharmacology.

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

D. Selley, S. Negus, Yunyun Yuan, 2015, Psychopharmacology.

Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

G. Kellogg, D. Selley, P. Mosier, 2013, Bioorganic & medicinal chemistry.

Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice

D. Selley, B. Cravatt, A. Lichtman, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats

D. Selley, J. Burston, J. Wiley, 2008, Neuropharmacology.

Brain regional differences in CB1 receptor adaptation and regulation of transcription.

D. Selley, L. Sim-Selley, M. Lazenka, 2013, Life sciences.

Inhibitory effects of SR141716A on G-protein activation in rat brain.

D. Selley, L J Sim-Selley, L K Brunk, 2001, European journal of pharmacology.

Integration of Molecular and Behavioral Approaches to Evaluate Cannabinoid Dependence

D. Selley, A. Lichtman, B. Martin, 2003 .

BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.

D. Selley, S. Childers, K. Chang, 1993, Molecular pharmacology.

β-Arrestin2 Regulates Cannabinoid CB1 Receptor Signaling and Adaptation in a Central Nervous System Region–Dependent Manner

Peter T. Nguyen, D. Selley, L. Bohn, 2012, Biological Psychiatry.

ABHD6 Blockade Exerts Antiepileptic Activity in PTZ-Induced Seizures and in Spontaneous Seizures in R6/2 Mice

Eric A. Horne, D. Selley, J. Oakley, 2014, Neuron.

N-Arachidonyl Maleimide Potentiates the Pharmacological and Biochemical Effects of the Endocannabinoid 2-Arachidonylglycerol through Inhibition of Monoacylglycerol Lipase

D. Selley, J. Burston, R. Razdan, 2008, Journal of Pharmacology and Experimental Therapeutics.

Effect of ΔFosB overexpression on opioid and cannabinoid receptor-mediated signaling in the nucleus accumbens

E. Nestler, D. Selley, M. Cassidy, 2011, Neuropharmacology.

Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus

D. Selley, W. Dewey, L. Sim-Selley, 2011, Brain Research.

Mice with Deficiency of G Protein γ3 Are Lean and Have Seizures

D. Selley, S. Bronson, J. Robishaw, 2004, Molecular and Cellular Biology.

Mice with deficiency of G protein gamma3 are lean and have seizures.

D. Selley, S. Bronson, J. Robishaw, 2004, Molecular and cellular biology.

Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity.

D. Selley, W. Dewey, Hongguang Ma, 2022, Journal of medicinal chemistry.

Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male mice

D. Selley, D. Bagdas, M. Damaj, 2018, Pharmacology Biochemistry and Behavior.

Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

D. Selley, W. Dewey, H. Akbarali, 2018, ACS chemical neuroscience.

Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone.

L. Vogt, D. Selley, S. Childers, 2000, European journal of pharmacology.

Effect of Ethanol Self‐Administration on μ‐ and δ‐Opioid Receptor‐Mediated G‐Protein Activity

L. Vogt, D. Selley, H. Samson, 2002 .

Effect of ethanol self-administration on mu- and delta-opioid receptor-mediated G-protein activity.

L. Vogt, D. Selley, H. Samson, 2002, Alcoholism, clinical and experimental research.

Region‐dependent attenuation of μ opioid receptor‐mediated G‐protein activation in mouse CNS as a function of morphine tolerance

D. Selley, L. Smith, W. Dewey, 2007, British journal of pharmacology.

Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy

D. Selley, W. Toma, M. Damaj, 2020, Psychopharmacology.

An essential role for ΔFosB in the nucleus accumbens in morphine action

D. Theobald, M. Kelz, E. Nestler, 2006, Nature Neuroscience.

An essential role for DeltaFosB in the nucleus accumbens in morphine action.

D. Theobald, M. Kelz, E. Nestler, 2006, Nature neuroscience.

Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Bethany A. Reinecke, D. Selley, Chongguang Chen, 2019, European journal of pharmacology.

Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.

D. Selley, L. Liu-Chen, Danni Cao, 2021, Future medicinal chemistry.

Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC 50,u and Correlation of in Vitro, Preclinical, and Clinical Data

D. Selley, J. C. Kalvass, Emily R. Olson, 2007 .

μ Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine 11Abbreviations: 6-MAM, 6-monoacetylmorphine; GTPγS, guanosine-5′-O-(γ-thio)-triphosphate; DAMGO, [d-Ala2,(N-Me)Phe4,Gly5(OH)]enkephalin; M-6-G, morphin

D. Selley, S. Childers, T. Sexton, 2001 .

Distinct patterns of ΔFosB induction in brain by drugs of abuse

D. Selley, E. Nestler, I. Maze, 2008, Synapse.

Cannabinoid receptor interacting protein suppresses agonist‐driven CB1 receptor internalization and regulates receptor replenishment in an agonist‐biased manner

C. Bass, D. Selley, S. Leone‐Kabler, 2016, Journal of neurochemistry.

∆9-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory

D. Selley, L. Wise, A. Lichtman, 2011, Psychopharmacology.

Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

E. Nestler, D. Selley, A. Lichtman, 2014, Biochemical pharmacology.

14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

D. Selley, Yan Zhang, Guo Li, 2009, Bioorganic & medicinal chemistry letters.

Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells.

C. Bass, D. Selley, A. Howlett, 2015, Cellular signalling.

ΔFosB induction correlates inversely with CB1 receptor desensitization in a brain region-dependent manner following repeated Δ9-THC administration

D. Selley, L. Sim-Selley, M. Lazenka, 2014, Neuropharmacology.

Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol–Mediated Induction of ΔFosB in the Mouse Forebrain

P. Greengard, D. Selley, M. Flajolet, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Role of dopamine type 1 receptors and DARPP-32 in Δ 9 -THC-mediated induction of Δ FosB in the mouse forebrain

P. Greengard, D. Selley, M. Flajolet, 2015 .

Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice

D. Selley, W. Dewey, J. Poklis, 2010, Brain Research.

Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.

D. Selley, S. Childers, Q. Liu, 1998, The Journal of pharmacology and experimental therapeutics.

mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.

D. Selley, S. Childers, Q. Liu, 1997, Molecular pharmacology.

Patient-controlled analgesia.

B. J. Harrison, Stephanie A. Carmack, John F. G. Atack, 1986, Nursing.

Molecular and behavioral mechanisms mediating paclitaxel‐induced changes in affect‐like behavior in mice

D. Selley, D. Bagdas, W. Toma, 2019, The FASEB Journal.

Δ9-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal Cortex

D. Selley, M. Lazenka, D. De, 2017, Cannabis and cannabinoid research.

Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol

D. Selley, M. LeDoux, M. Khan, 2019, Experimental Neurology.

Effects of intracerebroventricular administration of β‐funaltrexamine on DAMGO‐stimulated [35S]GTP‐γ‐S binding in rat brain sections

D. Selley, S. Childers, L. J. Sim, 1997, Synapse.

Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathy

D. Selley, W. Carlezon, E. Chartoff, 2019, Neuropharmacology.

Cannabinoid receptor interacting protein suppresses agonist‐driven CB1 receptor internalization and regulates receptor replenishment in an agonist‐biased manner

C. Bass, D. Selley, S. Leone‐Kabler, 2016, Journal of neurochemistry.

Cannabinoid Receptor–Interacting Protein 1a Modulates CB1 Receptor Signaling and Regulation

K. Mackie, M. Elphick, D. Selley, 2015, Molecular Pharmacology.

Posttranslational Protein Modification

Stephanie A. Carmack, John F. G. Atack, C. McDougle, 2021, Encyclopedia of Molecular Pharmacology.

In Vitro Autoradiographic Localization of Receptor-Stimulated [ 35 S]GTPγS Binding in Brain

D. Selley, S. Childers, L. J. Sim, 1997 .

Effects of Repeated Treatment with the Monoacylglycerol Lipase Inhibitor MJN110 on Pain-Related Depression of Nesting and Cannabinoid 1 Receptor Function in Male and Female Mice.

D. Selley, A. Lichtman, L. Sim‐Selley, 2024, The Journal of pharmacology and experimental therapeutics.

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

D. Selley, S. Negus, Yunyun Yuan, 2014, Psychopharmacology.

Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D2 and D3 Receptors

D. Grandy, D. Selley, M. Reith, 2015, Neurochemical Research.

Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer

Bethany A. Reinecke, D. Selley, Huijun Zhang, 2019, RSC medicinal chemistry.

Molecular Pharmacology Profiling of Phenylfentanil and Its Analogues to Understand the Putative Involvement of an Adrenergic Mechanism in Fentanyl-Induced Respiratory Depression.

D. Selley, Hongguang Ma, Yan Zhang, 2023, Journal of Medicinal Chemistry.

Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells

D. Selley, A. Lichtman, D. Gewirtz, 2014, The Journal of Pharmacology and Experimental Therapeutics.

JPET # 205120 2 Running Title : Combined WIN 55 , 212-2 and radiation in breast cancer

D. Selley, A. Lichtman, D. Gewirtz, 2013 .